Abstract: Although acute activation of the novel endocannabinoid receptor GPR18 causes hypotension, there are no reports on GPR18 expression in the heart or its chronic modulation of cardiovascular function. In this study, after demonstrating GPR18 expression in the heart, we show that chronic (2 weeks) GPR18 activation with its agonist abnormal cannabidiol (abn-cbd; 100 mg$kg 21 $d 21 ; i.p) produced hypotension, suppressed the cardiac sympathetic dominance, and improved left ventricular (LV) function (increased the contractility index dp/dt max and reduced LV end-diastolic pressure, LVEDP) in conscious rats. Ex vivo studies revealed increased: (1) cardiac and plasma adiponectin (ADN) levels; (2) vascular (aortic) endothelial nitric oxide synthase (eNOS) expression, (3) vascular and serum nitric oxide (NO) levels; (4) myocardial and plasma cyclic guanosine monophosphate (cGMP) levels; (5) phosphorylation of myocardial protein kinase B (Akt) and extracellular signal regulated kinase 1/2 (ERK1/2) along with reduced myocardial reactive oxygen species (ROS) in abn-cbd treated rats. These biochemical responses contributed to the hemodynamic responses and were GPR18-mediated because concurrent treatment with the competitive GPR18 antagonist (O-1918) abrogated the abn-cbd-evoked hemodynamic and biochemical responses. The current findings present new evidence for a salutary cardiovascular role for GPR18, mediated, at least partly, via elevation in the levels of adiponectin.
INTRODUCTION
There is growing interest in understanding the cardiovascular role of the endocannabinoid receptor GPR18, which is structurally distinct from the cannabinoid receptors 1 or 2 (CB 1 R/CB 2 R). 1 GPR18 was originally described as the endothelial cannabinoid receptor because its activation by the endogenous cannabinoid, ananedamide (AEA) or by the synthetic cannabinoid abnormal cannabidiol {trans-4-[3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol, abn-cbd} caused vasodilation and hypotension. 2, 3 Abrogation of the latter responses by the structural analogue of abn-cbd, O-1918 {(2)-1.3-dimethoxy-2-[3-3,4-trans-p-menthadien- (1, 8) -yl]-orcinol} [2] [3] [4] lead to categorizing the receptor as the ananedamide or abn-cbd receptor. Thereafter, the abn-cbd receptor was identified as GPR18 along with abn-cbd and O-1918 as its agonist and antagonist, respectively, 5 and N-arachidonyl glycine (NAGly) as its endogenous ligand. 6 Although GPR18 is considered the abn-cbd receptor, 5, 7 failure of abn-cbd or NAGly to produce GPR18-dependent biochemical responses in some studies 8, 9 fueled a debate on whether GPR18 is indeed the abn-cbd receptor. It is possible that the biochemical responses are tissue/ cell type specific due to differences in the constitutive activity of GPR18. 9 Importantly, many studies supported the role of GPR18 in regulating the cardiovascular function because NAGly caused relaxation of isolated rat mesenteric arteries 10 and abn-cbd-induced vasorelaxant and hypotensive responses that were abrogated by the GPR18 antagonist O-1918 [2] [3] [4] 11 and are not dependent on CB 1 /CB 2 receptors. 2, 3, 12 Further, although the endocannabinoid receptor GPR55 was originally considered the putative abn-cbd receptor, 1, 13 it is imperative to note that the abn-cbd-evoked vasorelaxation and hypotension are not GPR55 dependent because these responses persisted in GPR55 knockout mice 7, 14 and because the GPR55 agonist O-1602 14, 15 does not lower blood pressure (BP). 15 As a G i /G 0 -protein coupled receptor, GPR18 mediates cyclic adenosine monophosphate (cAMP) reduction in vitro 6 and activation of the PI3K/Akt and ERK1/2 pathways. 3, 5, 16 These findings may implicate endothelial nitric oxide synthase (eNOS)/nitric oxide (NO) in the vasodilation and centrally mediated hypotensive responses, caused by GPR18 activation, 10, 16 because the PI3K/Akt-ERK1/2 pathway activates eNOS. 17 Notably, our recent findings highlighted a possible role for the anti-inflammatory peptide, adiponectin (ADN) in the GPR18-mediated increase in NO and decrease in reactive oxygen species (ROS) levels in the brain stem. 11, 16 The latter findings are consistent with reported ADNdependent increase in vascular eNOS-derived NO and decrease in ROS levels. 18 However, three fundamental issues need to be addressed to understand the cardiovascular role of GPR18. First, in the previous studies, the reported acute GPR18-mediated hypotensive response might have been confounded by the high abn-cbd doses and anesthesia. 2, 3 Second, it is not known if GPR18 is expressed in the heart and regulates cardiac function. Third, the molecular mechanisms implicated in the cardiovascular responses caused by chronic GPR18 activation need to be elucidated. In addition to gaining new insight into the role of GPR18 signaling in cardiovascular function, the findings of the present study might lead to clinically relevant information on the potential use of GPR18 agonists as promising new drugs for the treatment of cardiovascular anomalies.
The main objective of the present study was to investigate the effect of chronic GPR18 activation (abn-cbd) in the absence or presence of GPR18 blockade (O-1918) on BP and cardiac function and to elucidate the molecular mechanisms of the GPR18-mediated hemodynamic effects in conscious rats. To achieve these goals, hemodynamic measurements were conducted in conscious male rats treated with abn-cbd, O-1918 or their combination for 2 weeks. Blood and cardiovascular tissues, collected from the treatment and control groups at the conclusion of the study, were used for ex vivo biochemical studies.
METHODS

Preparation of the Rats
Male Wistar rats (250-300 g; Charles River Laboratories, Raleigh, NC) were used in the present study. Rats were housed 2 per cage in a room with a controlled environment at a constant temperature of 23 6 18C, 50% 6 10% humidity, and a 12-hour light/dark cycle. Food (Prolab Rodent Chow, Prolab RMH 3000; Granville Milling, Creedmoor, NC) and water were provided ad libitum. All surgical, experimental, and animal care procedures were conducted in accordance with, and approved by, the East Carolina University Institutional Animal Care and Use Committee and in accordance with the Guide for the Care and Use of Laboratory Animals (Institute for Laboratory Animal Research, 2011).
Hemodynamic Measurements
Measurements of mean arterial pressure (MAP), heart rate (HR), and left ventricular (LV) function were conducted in conscious unrestrained rats at the end of the 2-week treatment period. Arterial and LV catheterizations were done under sterile conditions and anesthesia using ketamine (9 mg/100 g) and xylazine (1 mg/100 g, i.p) as in our previous studies. [19] [20] [21] The rats were housed individually and allowed 24 hours to recover from anesthesia. On the day of the experiment, the catheters were connected to Gould-Statham pressure transducers (Gould Inc., Oxnard, CA) for hemodynamic measurements as in our previous studies. 19, 20 The measured LV function indices dp/dt max , dp/dt min and left ventricular enddiastolic pressure (LVEDP) reflect LV compliance and intravascular volume and pressure. 19 Mean arterial pressure was computed as [1/3 (systolic pressure-diastolic pressure) + diastolic pressure] and HR was extracted from BP values. BP and HR were allowed to stabilize for at least for 30 minutes before collecting and analyzing hemodynamic data over 1 hour using ML870 (Power Lab 8/30) and Lab Chart 7 software (AD Instruments, Colorado Spring, CO) as in our previous studies. 19, 20 
Frequency Domain Analysis
Frequency domain analysis, which determines the cardiac sympathetic and parasympathetic balance, was conducted, using software designed for rats (Nevrokard SA-BRS; Izola, Slovenia) as in our previous study. 22 Power of RR interval (RRI) spectral density oscillations were computed by 512-point fast Fourier transform and integrated over the specified low-frequency (LF, 0.25-0.75 Hz) to high-frequency (HF, 0.75-5.0 Hz) range. LF and HF values reflect sympathetic and parasympathetic dominance, respectively, whereas the RRI LF/HF ratio is a measure of sympathovagal balance. 23 However, some studies indicate that LF represents the changes in both sympathetic and parasympathetic activities 24 because the change in the total power will affect the LF and HF in the same direction. Notably, the calculation of LF RRI and HF RRI spectra in normalized units (n.u) will minimize this effect. 23 
Blood and Tissues Collection for Biochemical Studies
At the end of the in vivo measurements, blood was collected, centrifuged, and stored at 2808C until use. Then, animals were euthanized with a lethal dose of sodium pentobarbital (100 mg/kg), and the hearts and vascular tissues were removed, cleaned from blood, flash-frozen in 2-methylbutane on dry ice, and stored at 2808C until use. 19 
Western Blot Analysis
Heart and aortic tissues were homogenized on ice in lysis buffer (pH 7.5) containing 20 mM Tris, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM b-glycerolphosphate, 1 mM activated sodium orthovanadate, 1 mg/mL leupeptin, and protease inhibitor cocktail (Roche Diagnostics, Indianapolis, IN). Samples were centrifuged at 48C, and then protein content was determined in the supernatant by a standard Bio-Rad protein assay system (Bio-Rad Laboratories, Hercules, CA). Sodium dodecyl sulfate (SDS) polyacrylamide gel (NuPAGE 4%-12% Bis-Tris Gel; Invitrogen, Carlsbad, CA) was used to separate the proteins in each sample using MOPS NuPAGE running buffer. Proteins were transferred from the gels to nitrocellulose membranes using TransBlot SD transfer cell (Bio-Rad Laboratories) and were incubated at room temperature for 2 hours in Odyssey Blocking Buffer (LI-COR Biosciences, Lincoln, NE). Then, membranes were incubated at 48C overnight with a mouse monoclonal anti-GAPDH antibody (1:15,000; Abcam Inc, Cambridge, MA) and one of the following primary antibodies: rabbit polyclonal anti-GPR18 antibody (1:500; Assay Biotech, Sunnyvale, CA), rabbit polyclonal anti-ADN antibody (1:200; Abcam Inc., Cambridge, MA), rabbit polyclonal anti-eNOS (1:200; BD Biosciences, San Jose, CA), rabbit polyclonal anti-ERK1/2 antibody (1:500), rabbit polyclonal anti-Akt antibody (1:500), mouse monoclonal antiphospho-eNOS (pSer1177) antibody (1:200; BD Biosciences, San Jose, CA), mouse monoclonal antiphospho-ERK1/2 (pTyr202/Y204) antibody (1:500) or mouse monoclonal antiphospho-Akt (pSer473) antibody (1:500). Antibodies for Akt, p-Akt, ERK1/2, and pERK1/2 were obtained from Cell Signaling Technology Inc. (Danvers, MA). At the end of incubation, membranes were washed and incubated for 60 minutes with mixture containing IRDye 680-conjugated goat anti-mouse and IR Dye 800-conjugated goat anti-rabbit (1:15,000; LI-COR Biosciences). Bands were detected by Odyssey Infrared Imager and analyzed with Odyssey application software version 0.3 (LI-COR Biosciences). GPR18, ADN, and eNOS expressions were quantified against GAPDH, whereas myocardial p-ERK1/2, p-eNOS, and p-Akt were quantified against the corresponding total protein. Protein expression and enzymatic activity were presented as percent of control (vehicle treated rats) as previously reported. 11 
Dual Labeling Immunofluorescence
Sections (20 mm) from naïve rats' hearts (n = 5), fixed in 4% paraformaldehyde in phosphate-buffered saline (PBS) for 20 minutes, were washed with Tris-buffered saline (TBS) and incubated with blocking buffer for 2 hours and subsequently incubated for 48 hours with mixtures of rabbit polyclonal anti-GPR18 antibody (1:500; Assay Biotech, Sunnyvale, CA) and mouse myocyte-specific protein alpha actin (1:200; Sigma-Aldrich, St. Louis, MO) in the presence or absence of the GPR18 antibody blocking peptide (1:200; Santa Cruz, Dallas, TX). Then, sections were incubated in a mixture of fluorescein isothiocyanate-conjugated donkey anti-rabbit (1:200; Abcam Inc, Cambridge, MA) and Cy3-conjugated donkey anti-mouse (1:200; Abcam Inc, Cambridge, MA) for 2 hrs. A Zeiss LSM 510 confocal microscope (Carl Zeiss Inc, Thornwood, NY) was used for visualization and acquisition of the fluorescent images at the same brightness and contrast settings in accordance with established protocols in our laboratory. 11 
Immunohistochemistry
Six to 8 sections from each heart (20 mm) were cut at 2248C with a microtome cryostat (HM 505 E; Microm International GmbH, Walldorf, Germany). The avidinbiotin complex method was used according to the manufacturer's instruction (Vectastain ABC kit; Vector Laboratories, Burlingame, CA). For immunohistochemical detection of ADN, the heart sections were incubated with rabbit anti-ADN primary antibody (1:200; Abcam Inc, Cambridge, MA). After rinsing with TBS, 3 0 -diaminobenzidine (in dH 2 O), the sections were examined under a microscope (Nikon Diaphot 300; Nikon, Tokyo, Japan) for the appearance of reddish brown staining. After dehydration, the sections were sealed with Permount (Fisher Scientific Co, Pittsburgh, PA) observed under the microscope, and the images were processed and quantified in accordance with established protocols in our previous study. 25 
Measurement of Nitrate/nitrite (NOx)
Serum, vascular (aortic), and myocardial nitrate/nitrite levels (index of NO) were measured calorimetrically by commercially available kit according to the manufacturer's instructions (Cayman Chemical Company, Ann Arbor, MI) and reported study. 11 
Measurement of Myocardial and Plasma cGMP
Plasma and myocardial cGMP levels were measured by a commercially available cGMP enzyme immunoassay (EIA) kit (Cayman Chemical Co, Ann Arbor, MI) according to the manufacturer's instructions and reported study. 26 
Measurement of Plasma Adiponectin
ADN was measured in plasma using Rat Adiponectin EIA kit (B-Bridge International Inc, San Jose, CA) according to the manufacturer's instructions and reported study. 27 
Measurement of Myocardial ROS by DCFH-DA
Myocardial ROS level was measured by 2,7-dichlorodihydrofluorescin diacetate (DCFH-DA; Molecular Probe), which is oxidized by ROS and forms a fluorescent dicholorofluorescein (DCF) at excitation 485/emission 530 nm wavelengths as in our previous studies. 11, 19 EXPERIMENTAL DESIGN AND PROTOCOL
Experiment 1. Myocardial GPR18 Expression
In the absence of any reports on cardiac GPR18 expression, we conducted Western blot studies on the hearts of control rats (n = 5) along with parallel studies in the spleen FIGURE 2. Effect of 2-week treatment with the GPR18 agonist abn-cbd, its antagonist O-1918 (100 mg$kg 21 $d 21 , i.p, each) or their combination on LV maximum contraction velocity (dp/dt max ; A); LV maximum relaxation velocity (dp/dt min ; B); and LVEDP (C) in conscious male rats (n = 6-8). Values are mean 6 SEM. *P , 0.05 versus control. (rich in GPR18) and the liver (devoid of GPR18), as positive and negative controls, respectively, 28 to validate the findings. The specific anti-GPR18 antibody (Assay Biotech, Sunnyvale, CA) was quantified against GAPDH. Further, dual-labeling immunofluorescence studies were conducted on myocardial sections in accordance with established protocols in our laboratory 11 using rabbit anti-GPR18 antibody and the mouse myocyte-specific protein alpha actin in the absence or presence of the GPR18 antibody blocking peptide.
Experiment 2. Hemodynamic and Sympathovagal Effects of Chronic GPR18 Activation or Blockade
This experiment was done to elucidate the cardiovascular effects of chronic GPR18 activation and/or blockade in conscious rats. To achieve this goal, 4 groups of rats (n = 8 per group) received the following daily i.p. injection(s) for 2 weeks: (1) the vehicle, mixture of dimethyl sulfoxide (DMSO) and phosphate-buffered saline (1:3, pH 7.2); (2) abn-cbd (100 mg/kg, i.p); (3) O-1918 (100 mg/kg, i.p), or (4) O-1918 30 minutes before abncbd (100 mg/kg, each). The selected systemic abn-cbd dose, which was based on preliminary findings in conscious rats (data not shown), constituted at least 1/10th the doses used in previous studies using anesthetized mice. 2, 3, 14 The selected dose (100 mg/kg) of the GPR18 antagonist (O-1918) was based on its ability to abrogate the effects of abn-cbd when both drugs were used in equal doses. 3, 5, 14 At the end of the 2-week treatment period, hemodynamic and spectral analysis studies were conducted in conscious state as described under methods.
Experiment 3. Ex Vivo Biochemical Consequences of GPR18 Activation or Blockade
At the conclusion of the hemodynamic measurements under experiment 2, the rats were euthanized, and the tissues and blood were collected for conducting the following biochemical measurements: (1) myocardial GPR18 expression; (2) plasma and vascular NOx levels; (3) cardiac and plasma ADN and cGMP levels; (4) myocardial NOx and ROS levels; (5) myocardial and vascular eNOS expression, and (6) myocardial phosphorylated Akt, ERK1/2 and eNOS.
Drugs
Abn-cbd and O-1918 were purchased from Cayman Chemical (Ann Arbor, MI); each drug was dissolved in methylacetate and kept at 2208C. To prepare an aqueous solution of each drug, methyl acetate solvent is volatilized and then each drug was dissolved in mixture of (DMSO: BPS, 1:3; pH 7.2). DMSO was purchased from SigmaAldrich (St. Louis, MO).
Statistical Analysis
Baseline values of the hemodynamics, ventricular functions, and biochemical parameters were expressed as mean 6 SEM. Statistical analysis was done using a 1-way analysis of variance (ANOVA) followed by Tukey's post hoc test and Student's t test. Prism 5.0 software (Graph Pad Software Inc, San Diego, CA) was used to perform statistical analysis and P , 0.05 was considered significant.
RESULTS
Chronic GPR18 Activation Reduced BP and Cardiac Sympathetic Dominance While Improving the LV Function.
GPR18 activation (abn-cbd) significantly (P , 0.05) reduced BP (Fig. 1A) , had no effect on HR (Fig. 1B) , and improved LV function as demonstrated by the concomitant increase in LV contractility index, dp/dt max ( Fig. 2A ; P , 0.05), and the reduction in LVEDP ( Fig. 2C; P , 0.05) . The dp/dt min , which reflects the LV performance during relaxation, did not significantly change by GPR18 activation (Fig.  2B) . Frequency domain analysis revealed significant (P , 0.05) suppression of the sympathetic (LF RRI ), but no change in the parasympathetic (HF RRI ), component (lower LF/HF RRI ratio), which reflects a reduction in the sympathetic prevalence in abn-cbd-treated rats (Fig. 3) . Although GPR18 blockade (O-1918) had no significant effect on the measured variables (Figs. 1, 2) , it abrogated the improvement in LV function ( Fig. 2A, C) and the reductions in BP (Fig. 1A) and in the sympathetic prevalence (Fig. 3) caused by abn-cbd.
Myocardial GPR18 Expression
Western blots revealed GPR18 expression in the heart and the findings were verified by incorporating positive (spleen) and negative (liver) controls (Fig. 4A) . Immunofluorescence findings in the absence and presence of the GPR18 blocking peptide further verified the GPR18 expression in cardiac myocytes (Fig. 4B) . Chronic (2 weeks) treatment with abn-cbd and/or O-1918 had no effect on myocardial GPR18 expression (Fig. 4C) .
GPR18 Activation Increased Circulating Levels of NO and ADN and Vascular eNOS/NO Levels.
Chronic abn-cbd administration significantly (P , 0.05) increased circulating ADN (Fig. 5A) and NO (Fig. 5B ) levels along with a significant (P , 0.05) increase in vascular eNOS/ NO levels (Fig. 5C, D) . On the other hand, chronic GPR18 blockade (O-1918) alone significantly (P , 0.05) reduced vascular eNOS/NO levels (Figs. 5C, D) and abrogated the abn-cbd evoked increases in circulating ADN (Fig. 5A) and NO (Fig. 5B ) levels.
Chronic GPR18 Activation Increased Cardiac ADN and cGMP Levels and Enhanced Myocardial Akt and ERK1/2 Phosphorylation.
Chronic GPR18 activation (abn-cbd) significantly (P , 0.05) increased cardiac ADN (Fig. 6 ) levels and enhanced myocardial Akt and ERK1/2 phosphorylation (Figs. 7A, B ). Abn-cbd had no effect on myocardial eNOS expression/phosphorylation (Figs. 7C, D) or NO levels (Fig. 8A ), but significantly (P , 0.05) reduced myocardial ROS level (Fig. 8B) , and increased myocardial (Fig. 8C) and plasma (Fig. 8D ) cGMP level; these responses were abrogated by O-1918 (Fig. 8B-D) . Further, chronic GPR18 blockade (O-1918) caused significant (P , 0.05) reduction in myocardial NO (Fig. 8A) , which paralleled significant (P , 0.05) reductions in myocardial Akt and eNOS phosphorylation (Figs. 7A, D) , but had no effect on myocardial eNOS expression (Fig. 7C) . Finally, O-1918 abrogated the abn-cbd-evoked increases in cardiac ADN (Fig. 6 ), cardiac and circulating cGMP (Figs. 8C and D) levels and myocardial ERK1/2 phosphorylation (Fig. 7B) . These molecular responses paralleled the O-1918 abrogation of abn-cbd-evoked hemodynamic effects (Figs. 1, 2) in the same rats.
DISCUSSION
In the present study, chronic GPR18 activation (abncbd) reduced BP and cardiac sympathetic dominance along with improving LV function in conscious rats along with the following ex vivo biochemical effects: (1) elevated myocardial and circulating ADN and cGMP levels; (2) enhanced vascular (aortic) eNOS/NO and serum NO levels; (3) reduced myocardial oxidative stress, and activation of myocardial cell survival signaling molecules (Akt and ERK1/2). Equally important, when administered concurrently, the selective GPR18 antagonist O-1918 abrogated the biochemical and the cardiovascular effects of abn-cbd. Collectively, these findings identified molecular mechanisms that might explain the novel salutatory cardiovascular responses elicited by chronic GPR18 activation in conscious rats.
There is a growing interest in the role of the GPR18 agonist, abn-cbd, in cardiovascular regulation because it elicits hypotensive and vasodilator responses. [2] [3] [4] However, the acute abn-cbd-evoked hypotension might have been confounded by anesthesia, which influences cardiovascular responses, 29 or by nonselective activation of other cannabinoid receptors such as GPR55 1, 13, 30 by the high abn-cbd doses (.1 mg/kg) used in these studies. [2] [3] [4] Therefore, we addressed these limitations by studying the hemodynamic effects of a much lower dose of abn-cbd (100 mg/kg) in conscious rats. It is important to consider possible biased agonism for O-1918 at GPR18 because O-1918 increased calcium mobilization and mitogen-activated protein kinase (MAPK) activity in GPR18-transfected HEK293 cells. 31 However, the possibility that these effects of O-1918 are tissue specific reinforces the need for more studies to address this issue. 32 The hypotensive response caused by chronic abn-cbd administration (Fig. 1A) or by central abn-cbd administration in our recent study, 11 and the abrogation of these effects by O-1918, implicates GPR18 in these responses. Although abn-cbd is an agonist at both GPR18 5 and GPR55 13, 30 and activation of both receptors inhibits cAMP-dependent signaling in vitro, 33 the abn-cbd-evoked vasodilation and hypotension are not GPR55 dependent because they persisted in GPR55 knockout mice. 7, 14 Interestingly, a lack of HR change (Fig. 1B) , contrary to an expected reflex tachycardia to abn-cbd-evoked hypotension, might be explained by the concurrent reduction in sympathetic prevalence (Fig. 3C) . Notably, abn-cbd-evoked FIGURE 6. Effect of 2-week treatment with the GPR18 agonist abncbd, its antagonist O-1918 (100 mg$kg 21 $d 21 , i.p, each) or their combination on cardiac ADN levels measured by western blot analysis (A) and by immunohistochemical staining (B) in male rats (n = 6). Values are mean 6 SEM. *P , 0.05 versus control. bradycardia 14 was observed after acute high abn-cbd doses and in the presence of anesthesia, which suppresses baroreflexes. 34 The exact signaling mechanism implicated in the GPR18-mediated hypotension is still unknown. In reported studies, abn-cbd increased eNOS-derived NO in rabbit aortic endothelial cells 35 and NAGly-induced NO-dependent vasorelaxation in isolated mesenteric arteries. 10 Further, in our recent study, nNOS-derived NO contributed to the sympathoinhibition and hypotension caused by central GPR18 activation in conscious rats. 16 Here, we show, for the first time, that the GPR18 (abn-cbd)-mediated hypotension (Fig. 1A) was associated with increases in vascular (aortic) eNOS/NO (Figs. 5C, D) and in circulating NO and cGMP (Figs. 5B and   8D ) levels. The increase in the NO second messenger, cGMP, 36 which is consistent with abn-cbd-mediated increase in cGMP levels in endothelial cells, 4 supports NO involvement in GPR18-mediated hypotension. By contrast, other studies [2] [3] [4] 12 ruled out NO involvement in abn-cbd-evoked vasodilation and suggested a role for the release of the endothelium-derived hyperpolarizing factor (EDHF) in the observed vasodilation. Notably, the contribution of either NO or EDHF to vasorelaxtion is dependent on the size and location of the blood vessel and on the species used. 37 It is important to comment on whether the increase in the circulating ADN (Fig. 5A) contributed to, or resulted from, the hypotensive response observed in abn-cbd-treated rats. An elevated circulating level exists in patients with orthostatic hypotension and diabetes compared with diabetes only. 38 Notably, this is an association finding in patients also exhibited worse kidney function compared to patients with diabetes only. 38 On the other hand, other the present and findings support a causal role for ADN in abn-cbd-evoked hypotension. First, GPR18 is detected in white adipose tissue, the major source of ADN. 39 Second, ADN improves vascular endothelial function and causes vasodilation by increasing eNOS-derived NO, 18 which is consistent with the association between the elevation in circulating ADN (Fig. 5A ) and the increase in eNOS-derived NO (Fig. 5) and hypotension (Fig. 1A) in abn-cbd-treated rats. The abrogation of these responses by concurrent treatment with O-1918 supports GPR18 mediation of the biochemical and hypotensive responses elicited by abn-cbd.
Whether these GPR18-mediated signaling events are functionally relevant in the heart has not been investigated. Results of the present study contribute to the understanding of the role of GPR18 in heart physiology by demonstrating and validating, for the first time, GPR18 expression in the heart (Fig.  4A) , and by confirming the GPR18 location in cardiac myocytes (Fig. 4B) . Functionally, chronic GPR18 activation increased the index for myocardial contractility, dp/dt max ( Fig. 2A) , and reduced LVEDP (Fig. 2C) . Although the increase in dp/dt max might involve GPR18-mediated Ca 2+ influx, 4, 6 which increases myocardial contractility, 40 the reduced LVEDP (Fig. 2C ) may be partly explained by the abn-cbd-evoked hypotension (Fig.  1A) and by the increase in cardiac contractility (Fig. 2A) .
The present findings suggest a pivotal role for increases in circulating (Fig. 5A) and cardiac (Fig. 6 ) ADN levels in the GPR18 (abn-cbd)-mediated improvement of cardiac function ( Fig. 2A, C) . This premise is initially supported by ADN synthesis in cardiomyocytes. 41 Although ADN level is lower in heart than in plasma, 42 ADN functions in autocrine and paracrine manner to activate its myocardial ADN receptors, which are expressed in cardiomyocytes. 41, 42 This ADN action may result in ROS reduction, 43 at least partly, via an increase in tetrahydrobiopterin (BH 4 ), a critical factor for eNOS coupling, 18 and subsequently improves cardiac function. 44 Consistent with these findings, abn-cbd-treated rats exhibited elevations in plasma and cardiac ADN levels (Figs. 5A and 6), reduced myocardial ROS level (Fig. 8B) , and improved cardiac function ( Fig. 2A, C) . We also observed enhancement in myocardial Akt and ERK1/2 phosphorylation in abn-cbd-treated rats (Fig. 7A, B) , which is consistent with a recently established mechanistic role for the activation of PI3K/Akt in favorable cellular effects of ADN. 45 It is also notable that the GPR18-medited activation of Akt and ERK1/2 agrees with our recent study and others. 3, 16 These signaling molecules exert vital cellular roles including cell survival, 46 inhibition of apoptosis, 47 and ROS reduction. 16, 48 Although a pivotal role for ADN in the GPR18-mediated improvement of myocardial redox status and function in our study is likely, we must consider the association between elevated circulating ADN levels and increased risk for mortality and cardiac morbidity. 49 It is worth noting, however, that other association-based clinical studies linked lower circulating ADN levels to cardiovascular anomalies in diabetes. 50 Therefore, further research is needed to mechanistically evaluate the role of circulating ADN levels in health and pathological conditions. The unavailability of selective ADN receptor blockers to causally link ADN to the GPR18-mediated cardiovascular responses is considered a limitation of our present study. Although future studies in ADN receptor knockout mice are needed to address this limitation, O-1918 abrogation of the elevations in circulating and cardiac ADN (Figs. 5A and 6 ) and the improvement in cardiac function (Figs. 2A, C) , caused by abn-cbd, support a role for ADN in the GPR18 (abn-cbd)-mediated cardiac responses.
Finally, it is important to comment on the myocardial eNOS expression and phosphorylation and NO level in the hearts of abn-cbd-treated rats. First, although myocardial eNOS expression was not affected by GPR18 activation or blockade (Fig. 7C ), GPR18 blockade (O-1918) reduced myocardial eNOS phosphorylation and myocardial NO levels (Figs. 7D and 8A) . Although myocardial NO level was not altered in abn-cbd-treated rats (Fig. 8A) , there was a significant increase in its more stable second messenger cGMP and this increase was abrogated by O-1918 (Fig. 8C) . O-1918 effect on cardiac eNOS might result, at least partly, from a reduction in myocardial Akt phosphorylation (Fig. 7A ) because p-Akt increases NO levels via increased eNOS phosphorylation. 17 By contrast, vascular (aortic) eNOS expression increased and decreased, respectively, by GPR18 activation (abn-cbd) and blockade (O-1918) (Fig. 5D ). The differences in eNOS expression and phosphorylation and in NO and cGMP levels in the heart and in blood vessels might highlight tissue specificity to GPR18 activation. Future studies are warranted to investigate this possibility.
In conclusion, the current findings present new evidence for a salutary cardiovascular role for GPR18 in conscious rats mediated, at least partly, via elevations in myocardial and circulating levels of ADN, cGMP, activation of cell survival Akt and ERK1/2 phosphorylation, and myocardial ROS reduction (Fig. 9) . Our conclusions are supported by the ability of GPR18 blockade to abrogate the indicated biochemical and cardiovascular functional responses. Finally, the present study highlights GPR18 as a viable molecular target for developing new antihypertensive therapeutics that simultaneously improve cardiac function.
